The GFPC01-2018 study has enrolled 30 patients with METex14 NSCLC (enriched for PDL-1 positive and ever smokers) treated with nivolumab or pembrolizumab and showed an ORR of 36%, an mPFS of 4.9 months, and an OS of 13.4 months [116]. Here, CD274 is linked to non-small cell lung carcinoma.